ReviewActa pharmacologica Sinica2026
Protein-protein interaction-mediated signaling networks in ischemic stroke: from molecular mechanisms to therapeutic strategies.
Review in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathological progression of ischemic stroke is driven by a dynamic signaling network mediated by protein-protein interactions (PPI) that involves excitotoxicity, oxidative stress, neuroinflammation, and regulated cell death (RCD), ultimately leading to neurological dysfunctions. Instead of functioning independently, these PPI-driven pathways engage in extensive cross-talk, creating cycles that exacerbate the injury over both space and time. Therapeutic strategies designed to disrupt key nodal PPIs, comprising small molecule inhibitors, peptide mimetics, and chimeras targeting proteolysis (PROTACs), have shown promise. However, clinical translation faces several major challenges, including the structural complexity of PPIs, the efficiency of blood-brain barrier (BBB) penetration, and the adaptive, multifactorial nature of the ischemic cascade. Emerging approaches are now shifting from single-target inhibition to network-level intervention, utilizing artificial intelligence (AI)-guided drug development, multi-target PPI regulators, and context-responsive delivery systems to achieve spatiotemporal precision. Through the integration of multidisciplinary technologies and mechanism-driven innovative designs, PPI-targeted strategies provide a promising approach to reprogramming the ischemic brain for repair, moving beyond traditional neuroprotection to dynamic network medicine.
Indexed as
Identifiers
42575968What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.